https://www.selleckchem.com/pr....oducts/glutathione.h
002). The 6-month pain-free survival rates were 30% and 51% in the Re-RT and transarterial chemoembolization groups, respectively (P= .08). The median tumor reduction rates were -4% and 9% in the Re-RT and transarterial chemoembolization groups, respectively (P .001). The objective response rates were 0% and 11% in the Re-RT and transarterial chemoembolization groups, respectively (P= .29). No serious adverse events or complications were observed. Transarterial chemoembolization achieved a superior response rate and longer dura
Like
Comment
Share
